Mid-Term Assessment of the EU Drugs Strategy 2013-2020 and Final Evaluation of the Action Plan on Drugs 2013-2016
Sep 22, 2016
The report sets out the findings of an evaluation that assesses the degree of implementation of the EU Drugs Strategy 2013-2020 and the Action Plan 2013–2016 in all 28 EU Member States in terms of outputs and, where possible, impacts. The key recommendation for the European Commission is that a new Action Plan should be implemented for the period 2017–2020.
The aim of the EU Drugs Strategy 2013–2020 is to contribute to a reduction in drug demand and drug supply within the EU. The Strategy has so far been implemented by an Action Plan covering the period 2013–2016. The report sets out the findings of an evaluation that assesses the degree of implementation of the Strategy and the Action Plan in terms of outputs and, where possible, impacts. It looks at the extent to which the objectives of the Strategy have been achieved. The evaluation aims to provide evidence to support the European Commission's decision about whether to propose a new Action Plan for the period 2017–2020 and, if so, what changes would be needed compared to the current plan.
Through applying a mixed-methods approach, the evaluation examined the effectiveness, efficiency, relevance and coherence of the actions undertaken on the basis of the EU Drugs Strategy and the Action Plan, as well as their EU added value. The evaluation makes 20 recommendations, addressed to the European Commission, Member States, the European Council and other stakeholders. The key recommendation for the Commission is that a new Action Plan should be implemented for the period 2017–2020. This should be an updated version of the current Action Plan, rather than taking a new approach or introducing more new actions.
Introduction to the study
Evaluation of effectiveness
Evaluation of efficiency
Evaluation of relevance
Evaluation of coherence
Evaluation of EU added value